198 related articles for article (PubMed ID: 29398135)
1. Activation of podocyte Notch mediates early Wt1 glomerulopathy.
Asfahani RI; Tahoun MM; Miller-Hodges EV; Bellerby J; Virasami AK; Sampson RD; Moulding D; Sebire NJ; Hohenstein P; Scambler PJ; Waters AM
Kidney Int; 2018 Apr; 93(4):903-920. PubMed ID: 29398135
[TBL] [Abstract][Full Text] [Related]
2. Wt1a, Foxc1a, and the Notch mediator Rbpj physically interact and regulate the formation of podocytes in zebrafish.
O'Brien LL; Grimaldi M; Kostun Z; Wingert RA; Selleck R; Davidson AJ
Dev Biol; 2011 Oct; 358(2):318-30. PubMed ID: 21871448
[TBL] [Abstract][Full Text] [Related]
3. Genome-Wide Analysis of Wilms' Tumor 1-Controlled Gene Expression in Podocytes Reveals Key Regulatory Mechanisms.
Kann M; Ettou S; Jung YL; Lenz MO; Taglienti ME; Park PJ; Schermer B; Benzing T; Kreidberg JA
J Am Soc Nephrol; 2015 Sep; 26(9):2097-104. PubMed ID: 25636411
[TBL] [Abstract][Full Text] [Related]
4. Integration of Cistromic and Transcriptomic Analyses Identifies Nphs2, Mafb, and Magi2 as Wilms' Tumor 1 Target Genes in Podocyte Differentiation and Maintenance.
Dong L; Pietsch S; Tan Z; Perner B; Sierig R; Kruspe D; Groth M; Witzgall R; Gröne HJ; Platzer M; Englert C
J Am Soc Nephrol; 2015 Sep; 26(9):2118-28. PubMed ID: 25556170
[TBL] [Abstract][Full Text] [Related]
5. Aberrant Notch1-dependent effects on glomerular parietal epithelial cells promotes collapsing focal segmental glomerulosclerosis with progressive podocyte loss.
Ueno T; Kobayashi N; Nakayama M; Takashima Y; Ohse T; Pastan I; Pippin JW; Shankland SJ; Uesugi N; Matsusaka T; Nagata M
Kidney Int; 2013 Jun; 83(6):1065-75. PubMed ID: 23447065
[TBL] [Abstract][Full Text] [Related]
6. Hepatocyte growth factor signaling ameliorates podocyte injury and proteinuria.
Dai C; Saleem MA; Holzman LB; Mathieson P; Liu Y
Kidney Int; 2010 Jun; 77(11):962-73. PubMed ID: 20375988
[TBL] [Abstract][Full Text] [Related]
7. Notch signaling, wt1 and foxc2 are key regulators of the podocyte gene regulatory network in Xenopus.
White JT; Zhang B; Cerqueira DM; Tran U; Wessely O
Development; 2010 Jun; 137(11):1863-73. PubMed ID: 20431116
[TBL] [Abstract][Full Text] [Related]
8. Alternatively spliced isoforms of WT1 control podocyte-specific gene expression.
Lefebvre J; Clarkson M; Massa F; Bradford ST; Charlet A; Buske F; Lacas-Gervais S; Schulz H; Gimpel C; Hata Y; Schaefer F; Schedl A
Kidney Int; 2015 Aug; 88(2):321-31. PubMed ID: 25993318
[TBL] [Abstract][Full Text] [Related]
9. Lyso-Gb3 activates Notch1 in human podocytes.
Sanchez-Niño MD; Carpio D; Sanz AB; Ruiz-Ortega M; Mezzano S; Ortiz A
Hum Mol Genet; 2015 Oct; 24(20):5720-32. PubMed ID: 26206887
[TBL] [Abstract][Full Text] [Related]
10. Murine Denys-Drash syndrome: evidence of podocyte de-differentiation and systemic mediation of glomerulosclerosis.
Patek CE; Fleming S; Miles CG; Bellamy CO; Ladomery M; Spraggon L; Mullins J; Hastie ND; Hooper ML
Hum Mol Genet; 2003 Sep; 12(18):2379-94. PubMed ID: 12915483
[TBL] [Abstract][Full Text] [Related]
11. Foxc1 and Foxc2 are necessary to maintain glomerular podocytes.
Motojima M; Kume T; Matsusaka T
Exp Cell Res; 2017 Mar; 352(2):265-272. PubMed ID: 28223138
[TBL] [Abstract][Full Text] [Related]
12. TGF-beta1 reduces Wilms' tumor suppressor gene expression in podocytes.
Sakairi T; Abe Y; Kopp JB
Nephrol Dial Transplant; 2011 Sep; 26(9):2746-52. PubMed ID: 21378152
[TBL] [Abstract][Full Text] [Related]
13. Podocyte-specific deletion of signal transducer and activator of transcription 3 attenuates nephrotoxic serum-induced glomerulonephritis.
Dai Y; Gu L; Yuan W; Yu Q; Ni Z; Ross MJ; Kaufman L; Xiong H; Salant DJ; He JC; Chuang PY
Kidney Int; 2013 Nov; 84(5):950-61. PubMed ID: 23842188
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of miR-34c inhibits high glucose-induced apoptosis in podocytes by targeting Notch signaling pathways.
Liu XD; Zhang LY; Zhu TC; Zhang RF; Wang SL; Bao Y
Int J Clin Exp Pathol; 2015; 8(5):4525-34. PubMed ID: 26191142
[TBL] [Abstract][Full Text] [Related]
15. A murine model of Denys-Drash syndrome reveals novel transcriptional targets of WT1 in podocytes.
Ratelade J; Arrondel C; Hamard G; Garbay S; Harvey S; Biebuyck N; Schulz H; Hastie N; Pontoglio M; Gubler MC; Antignac C; Heidet L
Hum Mol Genet; 2010 Jan; 19(1):1-15. PubMed ID: 19797313
[TBL] [Abstract][Full Text] [Related]
16. Absence of miR-146a in Podocytes Increases Risk of Diabetic Glomerulopathy via Up-regulation of ErbB4 and Notch-1.
Lee HW; Khan SQ; Khaliqdina S; Altintas MM; Grahammer F; Zhao JL; Koh KH; Tardi NJ; Faridi MH; Geraghty T; Cimbaluk DJ; Susztak K; Moita LF; Baltimore D; Tharaux PL; Huber TB; Kretzler M; Bitzer M; Reiser J; Gupta V
J Biol Chem; 2017 Jan; 292(2):732-747. PubMed ID: 27913625
[TBL] [Abstract][Full Text] [Related]
17. WT1 is a key regulator of podocyte function: reduced expression levels cause crescentic glomerulonephritis and mesangial sclerosis.
Guo JK; Menke AL; Gubler MC; Clarke AR; Harrison D; Hammes A; Hastie ND; Schedl A
Hum Mol Genet; 2002 Mar; 11(6):651-9. PubMed ID: 11912180
[TBL] [Abstract][Full Text] [Related]
18. Down-regulation of Wt1 activates Wnt/β-catenin signaling through modulating endocytic route of LRP6 in podocyte dysfunction in vitro.
Jing Z; Wei-jie Y; Yi-Feng ZG
Cell Signal; 2015 Sep; 27(9):1772-80. PubMed ID: 26049137
[TBL] [Abstract][Full Text] [Related]
19. Melanocortin therapy ameliorates podocytopathy and proteinuria in experimental focal segmental glomerulosclerosis involving a podocyte specific non-MC1R-mediated melanocortinergic signaling.
Qiao Y; Wang P; Chang M; Chen B; Ge Y; Malhotra DK; Dworkin LD; Gong R
Clin Sci (Lond); 2020 Apr; 134(7):695-710. PubMed ID: 32167144
[TBL] [Abstract][Full Text] [Related]
20. Podocyte apoptosis in diabetic nephropathy by BASP1 activation of the p53 pathway via WT1.
Zhang Y; Xu C; Ye Q; Tong L; Jiang H; Zhu X; Huang L; Lin W; Fu H; Wang J; Persson PB; Lai EY; Mao J
Acta Physiol (Oxf); 2021 May; 232(1):e13634. PubMed ID: 33615732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
